Health
FDA approves new indication for drug to treat pediatric NDO patients – News-Medical.Net
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for…
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.
Today’s action is a positive step for the treatment of NDO in young patients. Mirabegron,…
-
General12 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
Noosa News11 hours agoMajor emergency rescue following boat capsizing off Main Beach on the Gold Coast
-
General10 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?
-
Noosa News13 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer